Time to results significantly shorter with QIAstat-Dx Respiratory SARS-CoV-2 Panel than with PCR
NIH Launches Trial of Antibody Drugs Against COVID-19
The phase 2 trial will assess effectiveness of monoclonal antibodies in conjunction with remdesivir
Sitagliptin May Cut Mortality in T2DM Patients With COVID-19
Sitagliptin at time of hospitalization linked to reduced mortality, improved clinical outcomes
Black Race Tied to COVID-19 Admissions, but Not Deaths
In-hospital mortality higher for Asian patients, despite lower risk for hospital admission
COVID-19 Antibody Treatment Study Paused
ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused ‘out of an abundance of caution’
Immune Responses Long-Lasting After Serious COVID-19
IgG levels remain elevated for four months in patients with symptoms lasting for 14 days
Individuals With Blood Group O Have Lower Risk for COVID-19
And more COVID-19 patients with blood group A or AB require mechanical ventilation, CRRT
COVID-19-Free Surgical Pathways May Aid Cancer Surgery Outcomes
Pulmonary complication, postoperative SARS-CoV-2 infection rates lower with COVID-19-free pathways
Second COVID-19 Vaccine Trial Paused for Unexplained Illness
Johnson & Johnson stopped its COVID-19 vaccine trial, which began phase 3 testing last month
Symptoms of COVID-19 Poor Marker for SARS-CoV-2 Infection
Only 13.9 percent of individuals with positive test reported specific symptoms on the day of the test